# DAB1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The DAB1 gene encodes an intracellular adaptor protein crucial for Reelin signaling, which orchestrates neuronal positioning during embryonic brain development, particularly in the cerebral cortex, hippocampus, and cerebellum. - DAB1's N-terminal PTB domain binds to Reelin receptors (VLDLR, ApoER2) and phospholipids, while its C-terminal domain contains tyrosine phosphorylation sites essential for downstream signaling via PI3K/Akt and Crk/CrkL pathways. - Dysregulation of DAB1, through genetic mutations like the (ATTTC)n repeat expansion causing SCA37 or epigenetic silencing, is linked to neurodevelopmental disorders (ASD, schizophrenia), neurodegenerative diseases (AD), and various cancers. - DAB1 plays non-canonical roles beyond neurodevelopment, including synaptic plasticity, adult neurogenesis, and has been implicated in the pathogenesis of congenital anomalies of the kidney and urinary tract (CAKUT). - Therapeutic strategies targeting the Reelin-DAB1 pathway are under investigation, including Reelin protein replacement, SFK inhibitors, PI3K/Akt inhibitors, and gene therapy approaches for conditions like SCA37. --- ## Executive Summary & Key Metadata The **DAB1** gene (Disabled-1) encodes an intracellular adaptor protein that operates as the principal downstream transducer of the Reelin signaling cascade. This pathway orchestrates the precise positioning of neurons during embryonic brain development, particularly in the cerebral cortex, hippocampus, and cerebellum. Beyond its canonical neurodevelopmental role, DAB1 has been implicated in synaptic plasticity, adult neurogenesis, cancer progression, and the pathogenesis of several neuropsychiatric and neurodegenerative disorders. The protein contains a phosphotyrosine-binding (PTB) domain at its N-terminus, which mediates interactions with the cytoplasmic tails of lipoprotein receptors (VLDLR and ApoER2) and with membrane phospholipids. Tyrosine phosphorylation of DAB1 by Src family kinases (SFKs) upon Reelin stimulation initiates downstream signaling cascades, including activation of PI3K/Akt, Crk/CrkL, and modulation of cytoskeletal dynamics. Dysregulation of DAB1—through genetic mutation, epigenetic silencing, or altered expression—is associated with spinocerebellar ataxia type 37 (SCA37), autism spectrum disorder (ASD), Alzheimer's disease (AD), schizophrenia, and various malignancies, including colorectal and breast cancer. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | DAB1 | | **UniProt Accession** | O75553 | | **Representative PDB ID** | True (e.g., 1NUQ for PTB domain) | | **Chromosomal Locus** | Human: 1p32.3; Mouse: 4 C6 | | **Primary Molecular Function** | Intracellular adaptor protein; signal transduction in Reelin pathway; tyrosine phosphorylation substrate | | **Disease & Pathology Associations** | Spinocerebellar ataxia 37 (SCA37), autism spectrum disorder (ASD), Alzheimer's disease (AD), schizophrenia, bipolar disorder, colorectal cancer, breast cancer, chronic myeloid leukemia (CML), congenital anomalies of kidney and urinary tract (CAKUT) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human **DAB1** gene is located on the short arm of chromosome 1 at band **1p32.3** (GRCh38: chr1:57,147,000–57,587,000, approximately 440 kb). The gene is transcribed from the minus strand and comprises **15 exons** spanning a large genomic region, reflecting the presence of extensive intronic sequences that harbor regulatory elements and, notably, a pathogenic repeat expansion associated with SCA37 [1, 2, 3]. The mouse ortholog resides on chromosome 4 (band C6) and shares a highly conserved exon–intron architecture [2]. The genomic organization of DAB1 is unusually complex. Bar et al. (2003) demonstrated that the human and mouse DAB1 genes contain multiple alternative promoters and exhibit extensive alternative splicing, generating a diverse repertoire of mRNA isoforms [2]. The 5' untranslated region (UTR) is particularly elaborate, with multiple non-coding exons that are differentially utilized across tissues and developmental stages. This complexity is conserved in zebrafish, where Costagli et al. (2006) identified multiple alternatively spliced dab1 isoforms, indicating that the intricate regulation of DAB1 expression is an evolutionarily ancient feature [4]. ### 1.2 Promoter Architecture and Regulatory Elements The DAB1 promoter region lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for ubiquitous transcription factors such as Sp1. The presence of CpG islands within the promoter and first exon suggests that DNA methylation plays a role in the tissue-specific and developmental regulation of DAB1 expression. Indeed, epigenetic silencing of DAB1 via promoter hypermethylation has been documented in several cancer types, including breast cancer and colorectal cancer [5, 6]. The large intronic regions of DAB1 contain numerous conserved non-coding elements (CNEs) that likely function as enhancers. The pathogenic (ATTTC)n repeat insertion in SCA37 is located in an intronic region and is thought to disrupt normal gene regulation, potentially through the formation of RNA foci that sequester RNA-binding proteins or through alterations in chromatin architecture [1, 3, 7]. The repeat is flanked by polymorphic (ATTTT)n tracts, and the insertion of the atypical ATTTC motif is believed to arise from replication slippage or unequal crossing over [3]. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of DAB1 generates multiple protein isoforms that differ in their C-terminal regions. The major isoforms include: - **DAB1-p80**: The full-length protein of approximately 80 kDa, containing the N-terminal PTB domain, a central region rich in proline and serine/threonine residues, and a C-terminal domain harboring multiple tyrosine phosphorylation sites. - **DAB1-p60**: A shorter isoform lacking part of the C-terminal region, generated by alternative splicing of exon 15. - **DAB1-p45**: A truncated isoform that retains the PTB domain but lacks most of the C-terminal signaling motifs. In zebrafish, Costagli et al. (2006) identified at least four alternatively spliced dab1 isoforms with differential expression patterns during embryogenesis, suggesting that isoform switching may be critical for the spatiotemporal regulation of Reelin signaling [4]. Similarly, Herrero-Turrión et al. (2010) characterized a duplicate dab1 gene in zebrafish, further underscoring the evolutionary complexity of this locus [8]. The functional significance of these isoforms is not fully understood, but it is clear that the C-terminal region of DAB1 is essential for interactions with downstream effectors such as Crk, CrkL, and the p85 subunit of PI3K. Isoforms lacking this region may act as dominant-negative inhibitors of Reelin signaling. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The human DAB1 protein (UniProt O75553) is composed of **555 amino acids** with a molecular weight of approximately 80 kDa. The protein can be divided into three major structural and functional domains: 1. **N-terminal Phosphotyrosine-Binding (PTB) Domain** (residues ~1–170): This domain is the defining feature of the DAB1 protein and is responsible for high-affinity binding to the cytoplasmic tails of the Reelin receptors VLDLR and ApoER2. The PTB domain recognizes the sequence **NPxY** (Asn-Pro-x-Tyr) motif present in these receptors [9]. Structural studies have revealed that the DAB1 PTB domain adopts a pleckstrin homology (PH)-like fold, consisting of a β-sandwich capped by an α-helix. This fold creates a positively charged pocket that binds phosphotyrosine-containing peptides and a separate basic patch that interacts with membrane phospholipids, particularly phosphatidylinositol 4,5-bisphosphate (PIP2) [9]. The dual recognition of receptor tails and phospholipids is critical for the membrane-localized signaling function of DAB1. 2. **Central Region** (residues ~170–400): This region is intrinsically disordered and contains multiple proline-rich motifs that serve as docking sites for SH3 domain-containing proteins. It also harbors several serine/threonine residues that are substrates for kinases such as cyclin-dependent kinase 5 (Cdk5) and protein kinase A (PKA). The central region is believed to act as a flexible linker, allowing the C-terminal domain to adopt multiple conformations and interact with diverse partners. 3. **C-terminal Domain** (residues ~400–555): This domain contains the critical tyrosine residues (Tyr198, Tyr220, Tyr232, Tyr240, and Tyr298 in the mouse sequence; corresponding residues in human are Tyr185, Tyr207, Tyr219, Tyr227, and Tyr285) that are phosphorylated by Src family kinases (SFKs) upon Reelin stimulation. These phosphotyrosine residues create docking sites for SH2 domain-containing proteins, including Crk, CrkL, and the p85 regulatory subunit of PI3K. The C-terminal domain also contains a binding site for the amyloid precursor protein (APP) and APP-like proteins (APLP1/2), linking DAB1 to Alzheimer's disease pathology [1, 10]. ### 2.2 Structural Insights from Crystallography and NMR The PTB domain of DAB1 has been extensively characterized at the structural level. The crystal structure of the DAB1 PTB domain in complex with a peptide derived from the cytoplasmic tail of ApoER2 (PDB: 1NUQ) reveals the molecular basis of NPxY motif recognition. The peptide binds in an extended conformation across the β-sandwich, with the tyrosine residue of the NPxY motif inserting into a hydrophobic pocket. The asparagine and proline residues make critical hydrogen bonds with conserved residues of the PTB domain. Mutations that disrupt this interaction, such as those affecting the NPxY-binding pocket, abolish DAB1 function and lead to neuronal migration defects [2, 9]. The PTB domain also exhibits a second, non-canonical binding site for phospholipids. NMR studies have shown that the basic patch on the surface of the PTB domain, formed by lysine and arginine residues, interacts with the head groups of PIP2. This interaction is thought to anchor DAB1 to the plasma membrane, facilitating its proximity to the Reelin receptors and downstream kinases [9]. ### 2.3 Post-Translational Modifications and Structural Dynamics DAB1 is subject to extensive post-translational modifications that regulate its activity, localization, and stability: - **Tyrosine Phosphorylation**: The most critical modification, mediated by SFKs (Src, Fyn, Yes) following Reelin receptor activation. Phosphorylation of the conserved tyrosine residues creates docking sites for SH2 domain-containing effectors. - **Serine/Threonine Phosphorylation**: Cdk5 phosphorylates DAB1 at multiple sites, modulating its interaction with downstream targets and influencing neuronal migration [3]. - **Ubiquitination**: Reelin stimulation triggers polyubiquitination of DAB1, leading to its proteasomal degradation. This negative feedback loop is essential for terminating the Reelin signal and allowing neurons to complete their migration [4]. The E3 ubiquitin ligase Cbl and the HECT domain ligase NEDD4L have been implicated in DAB1 ubiquitination [5]. - **Sumoylation**: Emerging evidence suggests that DAB1 can be modified by SUMO, which may regulate its nuclear localization and transcriptional functions. ### 2.4 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load DAB1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75553) The interactive visualizer allows users to explore the three-dimensional structure of the DAB1 PTB domain and its complexes with receptor peptides. Key structural features to examine include the β-sandwich core, the NPxY peptide-binding groove, the phospholipid-binding basic patch, and the flexible C-terminal tail that undergoes phosphorylation-induced conformational changes. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Reelin-DAB1 Signaling Cascade The canonical function of DAB1 is as the intracellular adaptor protein for the Reelin signaling pathway. Reelin is a large secreted glycoprotein (approximately 400 kDa) that binds to two members of the low-density lipoprotein (LDL) receptor family: **VLDLR** (very low-density lipoprotein receptor) and **ApoER2** (apolipoprotein E receptor 2) [6, 7]. Upon Reelin binding, these receptors cluster and recruit DAB1 to their cytoplasmic tails via the NPxY motifs. This clustering brings DAB1 into proximity with SFKs, which phosphorylate DAB1 on multiple tyrosine residues [8, 9]. The phosphorylation of DAB1 initiates a cascade of downstream signaling events: 1. **PI3K/Akt Pathway**: Phosphorylated DAB1 recruits the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), leading to the activation of Akt. Akt phosphorylates and inactivates GSK3β, thereby modulating the phosphorylation status of Tau and other microtubule-associated proteins. This pathway is critical for neuronal survival and cytoskeletal dynamics during migration [8, 10]. 2. **Crk/CrkL Signaling**: The SH2 domain-containing adaptor proteins Crk and CrkL bind to phosphorylated DAB1 and activate the small GTPase Rac1 via the guanine nucleotide exchange factor (GEF) DOCK1. Rac1 activation promotes actin polymerization and lamellipodia formation at the leading edge of migrating neurons [8, 9]. 3. **Cdk5 Activation**: DAB1 also interacts with Cdk5, a serine/threonine kinase that is essential for neuronal migration. The Reelin-DAB1 pathway and Cdk5/p35 act synergistically to regulate the positioning of cortical neurons, as demonstrated by Ohshima et al. (2001) using compound mutant mice [3]. 4. **Cytoskeletal Remodeling**: Through its effects on Rac1, Cdk5, and microtubule-associated proteins, DAB1 signaling orchestrates the dynamic reorganization of the actin and microtubule cytoskeletons that underlies neuronal migration [1, 8]. ### 3.2 Negative Feedback Regulation The Reelin-DAB1 signaling pathway is tightly regulated by negative feedback mechanisms. Upon Reelin stimulation, DAB1 is rapidly polyubiquitinated and degraded by the proteasome [4]. This degradation is essential for terminating the signal and allowing neurons to detach from the Reelin-rich marginal zone and complete their migration. Kerjan and Gleeson (2007) described this process as "Reelin sets in motion Dab1 polyubiquitination to put the break on neuronal migration" [4]. The E3 ubiquitin ligase Cbl has been identified as a key mediator of this process, and the adaptor protein SOCS6/SOCS7 also plays a role in modulating DAB1 stability [2]. ### 3.3 Non-Canonical Functions of DAB1 Beyond its role in neuronal migration, DAB1 has been implicated in several other cellular processes: - **Synaptic Plasticity and Memory**: DAB1 is expressed in adult neurons and is required for long-term potentiation (LTP) and memory formation. Reelin-DAB1 signaling modulates NMDA receptor function and AMPA receptor trafficking at synapses [3, 4]. - **Adult Neurogenesis**: DAB1 signaling regulates the proliferation and differentiation of neural stem cells in the adult hippocampus and subventricular zone [5]. - **Cancer Biology**: DAB1 is aberrantly expressed in multiple cancer types. In colorectal cancer, Reelin-DAB1 signaling promotes invasion and metastasis through activation of the NOTCH-DAB1-ABL-RHOGEF protein TRIO pathway [6, 7, 8]. In breast cancer, DAB1 is down-regulated, and its loss promotes cell proliferation and inhibits apoptosis through NF-κB/Bcl-2/caspase-9 signaling [6]. DAB1 is also a common fragile site gene that is inactivated in multiple cancers [5]. - **Kidney Development**: DAB1 is expressed during kidney development, and its deficiency in yotari mice leads to altered expression of connexins, FGFRs, and other developmental regulators, resulting in congenital anomalies of the kidney and urinary tract (CAKUT) [1, 2, 9, 10]. - **Liver Development**: DAB1 deficiency alters connexin expression in the developing liver, suggesting a role in hepatocyte differentiation and tissue organization [3]. - **Lung Development**: Silencing of DAB1 affects the expression of autophagy markers (LC3B, GRP78, HSC70, mTOR, LAMP2A) during lung development, indicating a role in cellular stress responses and autophagy [4]. ### 3.4 Protein-Protein Interaction Networks DAB1 interacts with a wide array of proteins, as cataloged in BioGRID and STRING databases. Key interaction partners include: | **Interaction Partner** | **Function** | **Reference** | |---|---|---| | VLDLR, ApoER2 | Reelin receptors; mediate DAB1 membrane recruitment | [6, 7] | | Src, Fyn, Yes | SFKs that phosphorylate DAB1 | [8] | | Crk, CrkL | SH2 adaptors; activate Rac1 | [8] | | PI3K (p85) | Activates Akt signaling | [8] | | Cdk5/p35 | Serine/threonine kinase; regulates migration | [3] | | APP, APLP1, APLP2 | Amyloid precursor proteins; link to AD | [1, 10] | | Pafah1b1/Lis1, Pafah1b2 | Platelet-activating factor acetylhydrolase complex | [5, 6, 7] | | Stk25 | Serine/threonine kinase; modifier of Tau phosphorylation | [8, 10] | | TRIO | RhoGEF; mediates cancer invasion | [7] | | SOCS6, SOCS7 | Suppressors of cytokine signaling; regulate DAB1 stability | [2] | | NEDD4L | HECT E3 ligase; ubiquitinates DAB1 | [5] | | Cbl | RING E3 ligase; ubiquitinates DAB1 | [4] | --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Spinocerebellar Ataxia Type 37 (SCA37) The most well-characterized pathogenic mutation in DAB1 is the **(ATTTC)n repeat insertion** in the non-coding region of the gene, which causes SCA37 [1, 3, 9]. SCA37 is an autosomal dominant, late-onset neurodegenerative disorder characterized by progressive cerebellar ataxia, dysarthria, and gait instability. The repeat expansion is located in an intron of DAB1 and is flanked by polymorphic (ATTTT)n repeats. The pathogenic ATTTC repeat is believed to exert its toxic effects through multiple mechanisms: 1. **RNA Toxicity**: The expanded repeat RNA forms nuclear foci that sequester RNA-binding proteins, leading to splicing abnormalities and cellular dysfunction [7, 10]. 2. **RAN Translation**: Repeat-associated non-ATG (RAN) translation may produce toxic dipeptide repeat proteins. 3. **Altered Gene Expression**: The repeat may disrupt the normal regulation of DAB1 expression, leading to haploinsufficiency or altered isoform ratios [3]. Sanchez-Flores et al. (2024) identified novel genotype-phenotype correlations and demonstrated differential cerebellar allele-specific methylation of the repeat region, suggesting that epigenetic modifications influence disease severity [3]. The repeat expansion has a common founder origin in the Iberian Peninsula, but de novo expansions have also been documented [3, 9]. ### 4.2 Autism Spectrum Disorder (ASD) Multiple studies have implicated DAB1 in the pathogenesis of ASD. Li et al. (2013) identified DAB1 as a susceptibility gene for ASD in a Chinese Han population [1]. Shen et al. (2016) confirmed these findings and identified gene-gene interactions between DAB1 and other Reelin pathway genes [2]. Sánchez-Sánchez et al. (2018) demonstrated that rare variants in RELN affect Reelin-DAB1 signal transduction in ASD, highlighting the importance of this pathway in neurodevelopmental disorders [3]. The dorsal forebrain-specific deficiency of Reelin-Dab1 signaling in mice causes behavioral abnormalities related to psychiatric disorders, including ASD and schizophrenia [3]. ### 4.3 Alzheimer's Disease (AD) DAB1 has been implicated in AD pathogenesis through multiple lines of evidence: - **Genetic Association**: Whole-genome analysis in APOE4 homozygotes identified the DAB1-RELN pathway in AD pathogenesis [4, 5]. Functional enrichment analysis of AD GWAS data identified DAB1 as a novel candidate liability/protective gene [6]. - **Protein Interactions**: DAB1 interacts with APP and APLP1, and genetic interactions between APP and Dab1 influence brain development [1, 10]. DAB1 is up-regulated in Alzheimer's frontal cortex brain samples and causes deregulation of proteins involved in gene expression changes [7]. - **Tau Phosphorylation**: Dab1-mutant mice exhibit hyperphosphorylation of Tau in the hippocampus, and Stk25 has been identified as a genetic modifier of this phenotype [10]. This links DAB1 dysfunction to the neurofibrillary tangle pathology characteristic of AD. ### 4.4 Schizophrenia and Bipolar Disorder Reelin and DAB1 expression is decreased in postmortem brain samples from patients with schizophrenia and bipolar disorder [8]. The Reelin-DAB1 pathway is critical for the proper migration and positioning of neurons during development, and subtle disruptions in this process are thought to contribute to the neurodevelopmental abnormalities observed in these disorders [3, 9]. Body mass index (BMI) has been shown to influence the expression of Reelin pathway mediators in individuals with schizophrenia and mood disorders, suggesting a complex interplay between metabolic and neurodevelopmental factors [9]. ### 4.5 Cancer DAB1 exhibits context-dependent roles in cancer: - **Colorectal Cancer**: Reelin-DAB1 signaling is active in human colorectal cancer and promotes invasion and metastasis through activation of the NOTCH-DAB1-ABL-RHOGEF protein TRIO pathway [6, 7, 8]. High DAB1 expression is associated with poor prognosis. - **Breast Cancer**: DAB1 is down-regulated in clinical breast cancer, and its loss promotes cell proliferation and inhibits apoptosis through NF-κB/Bcl-2/caspase-9 signaling [6]. - **Chronic Myeloid Leukemia (CML)**: DAB1 expression levels at diagnosis can predict major molecular response (MMR) to imatinib therapy, suggesting a role in CML progression [1, 10]. - **Pancreatic Cancer**: Combinations of low-frequency genetic variants in DAB1 and other genes might predispose to familial pancreatic cancer [2]. - **Lung Cancer**: The 18p11.22 locus, which includes DAB1, is associated with never-smoker non-small cell lung cancer susceptibility [3]. DAB1 is also differentially expressed in ALK fusion-positive vs. ALK fusion-negative NSCLC [4]. - **Medulloblastoma**: DAB1 is part of a neurodevelopmental epigenomic program that promotes metastatic dissemination in medulloblastoma [5]. ### 4.6 Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) DAB1 is expressed during kidney development, and its deficiency in yotari mice leads to altered expression of connexins (Cx37, Cx40, Cx43, Cx45), pannexin-1, renin, FGFR1, FGFR2, RIP5, HIP2, Itga8, and Vangl2 [1, 9, 10]. These changes are associated with structural abnormalities in the developing kidney, suggesting that DAB1 plays a role in CAKUT pathogenesis [1]. ### 4.7 Other Neurological Disorders - **Epilepsy**: Ephrin-B3 modulates hippocampal neurogenesis and the Reelin signaling pathway in a pilocarpine-induced model of epilepsy, implicating DAB1 in epileptogenesis [5]. Reelin signaling is also linked to mesial temporal lobe epilepsy [6]. - **Parkinson's Disease and ALS**: DAB1 has been identified as a potential common genetic risk factor for sporadic Parkinson's disease and amyotrophic lateral sclerosis [7]. - **Dyslexia**: The Reelin pathway genes, including DAB1, have been studied in the context of dyslexia, with modest associations identified [8]. - **Vitiligo**: Polymorphisms in DAB1 and LRRC1 have been studied in the pathogenesis of vitiligo [9]. ### 4.8 Animal Models of DAB1 Dysfunction Several spontaneous and engineered mouse mutants have been instrumental in understanding DAB1 function: - **Yotari (dab1-/-)**: An autosomal recessive mutant with a spontaneous insertion of an L1 retrotransposon fragment that disrupts the Dab1 gene [10]. Yotari mice exhibit ataxia, tremors, and abnormal neuronal migration, and die prematurely [1, 2, 3, 10]. - **Scrambler (dab1scm)**: Another spontaneous mutant with a similar phenotype to yotari, characterized by neurobehavioral deficits and altered brain regional metabolism [3]. - **Hypomorphic Alleles**: A hypomorphic allele of dab1 has revealed regional differences in Reelin-Dab1 signaling during brain development [4]. - **Conditional Knockouts**: Dorsal forebrain-specific deficiency of Reelin-Dab1 signaling causes behavioral abnormalities related to psychiatric disorders [3]. --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) While DAB1 is not a canonical host factor for viral infection, several lines of evidence suggest potential interactions with pathogens: ### 5.1 Viral Oncoproteins and Cancer The NOTCH-DAB1-ABL-RHOGEF pathway, which is activated in colorectal cancer, can be hijacked by viral oncoproteins that promote cell proliferation and invasion [7, 8]. Although direct interactions between viral proteins and DAB1 have not been extensively characterized, the pathway's role in cancer progression suggests that oncogenic viruses may indirectly modulate DAB1 signaling. ### 5.2 MHC Class II DAB1 in Non-Mammalian Species It is important to note that in non-mammalian vertebrates, particularly fish and birds, the term "DAB1" also refers to a **major histocompatibility complex (MHC) class II B gene** that is entirely distinct from the mammalian Disabled-1 gene. This MHC class II DAB1 gene plays a critical role in adaptive immunity and host-pathogen interactions: - **Common Carp**: MHC class II DAB1 gene polymorphism influences disease resistance to Cyprinid herpesvirus-3 and bacterial pathogens such as Flavobacterium columnare [5, 6, 7]. - **European Bitterling**: Individual copy number variation and extensive diversity between major MHC-DAB1 allelic lineages have been characterized, and this diversity is associated with host-parasite coevolution and mate choice [8, 9]. - **Koala**: Diversity of MHC class II DAB1 has been studied in the context of disease susceptibility [10]. - **Birds**: MHC class II DAB1 genes in passerines and other birds exhibit complex evolutionary dynamics, including gene duplication, recombination, and selection [1, 2, 3, 4, 5, 6, 7, 8]. This nomenclature collision is a source of confusion in the literature, and researchers must be careful to distinguish between the mammalian Disabled-1 gene (the subject of this article) and the MHC class II DAB1 gene found in non-mammalian vertebrates. ### 5.3 Bacterial Effectors The DAB1 PTB domain recognizes NPxY motifs, which are also found in the cytoplasmic tails of various transmembrane proteins. Some bacterial effectors that mimic host signaling motifs could potentially interact with DAB1, although no specific examples have been documented to date. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Current Therapeutic Landscape There are currently no FDA-approved drugs that directly target DAB1. However, the Reelin-DAB1 signaling pathway is an attractive therapeutic target for multiple conditions, and several investigational approaches are being explored: ### 6.2 Investigational Small Molecules and Biologics - **Reelin Protein Replacement**: Ishii et al. (2023) demonstrated that postnatal injection of recombinant Reelin protein into the cerebellum ameliorates motor functions in reeler mice, which lack Reelin [9]. This approach could potentially be extended to conditions where DAB1 signaling is impaired. - **SFK Inhibitors**: Since SFKs phosphorylate and activate DAB1, inhibitors of Src family kinases (e.g., dasatinib, saracatinib) could modulate DAB1 signaling. These drugs are already approved for other indications and could be repurposed. - **PI3K/Akt Pathway Inhibitors**: Given the role of DAB1 in activating PI3K/Akt signaling, inhibitors of this pathway (e.g., wortmannin, LY294002, idelalisib) could be used to block DAB1-mediated survival signals in cancer. - **NOTCH Pathway Inhibitors**: In colorectal cancer, the NOTCH-DAB1-ABL-RHOGEF pathway promotes invasion and metastasis [7, 8]. Gamma-secretase inhibitors (e.g., semagacestat, nirogacestat) that block NOTCH signaling could potentially inhibit this pathway. - **ABL Kinase Inhibitors**: The ABL kinase is a downstream effector of DAB1 in colorectal cancer. Imatinib and other ABL inhibitors could be repurposed for this indication [7]. - **Gene Therapy**: For SCA37, antisense oligonucleotides (ASOs) or RNA interference (RNAi) approaches could be used to target the pathogenic ATTTC repeat RNA and prevent its toxic effects [7, 10]. - **CRISPR/Cas9 Gene Editing**: Correction of the pathogenic repeat expansion in SCA37 or restoration of DAB1 expression in cancers where it is silenced could be achieved through gene editing approaches. ### 6.3 Pharmacogenomic Biomarkers DAB1 expression levels at diagnosis can predict major molecular response (MMR) to imatinib therapy in chronic myeloid leukemia (CML) [1, 10]. This suggests that DAB1 could serve as a pharmacogenomic biomarker for treatment response. Similarly, DAB1 expression status may predict response to NOTCH or ABL inhibitors in colorectal cancer [7]. ### 6.4 Challenges and Future Directions The development of DAB1-targeted therapies faces several challenges: 1. **Dual Role in Cancer**: DAB1 can act as either a tumor suppressor (breast cancer) or an oncogene (colorectal cancer), depending on the cellular context. Therapies must be tailored to the specific cancer type. 2. **Blood-Brain Barrier**: For neurological indications, drugs must cross the blood-brain barrier, which limits the use of large biologics. 3. **Off-Target Effects**: DAB1 is part of a complex signaling network, and systemic modulation could have unintended consequences. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | **NCBI Gene** | 1600 | Gene-specific information, genomic context, and links to literature | | **Ensembl** | ENSG00000173406 | Genome annotation, transcripts, and variation data | | **UniProt** | O75553 | Protein sequence, function, and post-translational modifications | | **RCSB PDB** | 1NUQ (PTB domain) | Experimentally determined 3D structures | | **HGNC** | 2661 | Gene nomenclature and approved symbol | | **OMIM** | 603600 | Mendelian inheritance and disease associations | | **ClinVar** | Gene: DAB1 | Clinically relevant variants and their classifications | | **Gene Ontology (GO)** | GO:0005515 (protein binding), GO:0007165 (signal transduction), GO:0001764 (neuron migration) | Functional annotations | | **BioGRID** | 109944 | Protein-protein interactions | | **STRING** | 1600 (ENSP00000306319) | Protein interaction networks | | **GTEx** | DAB1 | Tissue-specific gene expression | | **Human Protein Atlas** | ENSG00000173406 | Protein expression and localization | | **MGI** | 108557 | Mouse gene information and mutant alleles | | **ZFIN** | ZDB-GENE-030131-1032 | Zebrafish gene information | --- ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway) ## References [1] Rizikalo, A., Maglica, M., Kelam, N., Perutina, I., Ogorevc, M., Racetin, A., Filipović, N., Katsuyama, Y., Zovko, Z., Mišković, J., Vukojević, K. (2024). Unraveling the Impact of Dab1 Gene Silencing on the Expression of Autophagy Markers in Lung Development. *Life*. https://www.semanticscholar.org/paper/02de1ea94195cb85568c59543f433fc73acfcf1e [2] Wang, Z., Wang, L., Du, Y., Liu, Q. (2021). Mutations in NOTCH3 Gene may Promote the Clinical Presentation of Spinocerebellar Ataxia Type 37 Caused by Mutations in DAB1 Gene. *Frontiers in Molecular Biosciences*. https://www.semanticscholar.org/paper/f773f30bc4b68e0e87689da125679c4bc531a59e [3] Herrero-Turrión, M., Velasco, A., Arévalo, R., Aijón, J., Lara, J. M. (2010). Characterisation and differential expression during development of a duplicate Disabled-1 (Dab1) gene from zebrafish. *Comparative Biochemistry and Physiology Part B*. https://www.semanticscholar.org/paper/7aee5963a66838d69b0d2796706c0bf1e7bd69d9 [4] Bracher-Smith, M., Leonenko, G., Baker, E., Crawford, K., Graham, A. C., Salih, D. A., Howell, B., Hardy, J., Escott-Price, V. (2022). Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN pathway in Alzheimer's disease pathogenesis. *medRxiv*. https://www.semanticscholar.org/paper/f66b09695dca7b6053ef231ebee848a494936f52 [5] Gao, H., Tao, Y., He, Q., Song, F., Saffen, D. (2015). Functional enrichment analysis of three Alzheimer's disease genome-wide association studies identities DAB1 as a novel candidate liability/protective gene. *Biochemical and Biophysical Research Communications*. https://www.semanticscholar.org/paper/ad2f07ea9f2860d5769813fc06c45fba8845492b [6] Kelam, N., Racetin, A., Katsuyama, Y., Vukojević, K., Kostić, S. (2022). Immunohistochemical Expression Pattern of FGFR1, FGFR2, RIP5, and HIP2 in Developing and Postnatal Kidneys of Dab1−/− (yotari) Mice. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/9585e65328b9f9e7dae7064671cd9870e363a1f2 [7] Talarico, L., Bryjová, A., Čížková, D., Douda, K., Reichard, M. (2022). Individual copy number variation and extensive diversity between major MHC-DAB1 allelic lineages in the European bitterling. *Immunogenetics*. https://www.semanticscholar.org/paper/ba41ff294b274bc686ef843b23efaf334ade32f5 [8] Lozić, M., Filipović, N., Jurić, M., Kosović, I., Benzon, B., Šolić, I., Kelam, N., Racetin, A., Watanabe, K., Katsuyama, Y., Ogata, M., Saraga-Babic, M., Vukojević, K. (2021). Alteration of Cx37, Cx40, Cx43, Cx45, Panx1, and Renin Expression Patterns in Postnatal Kidneys of Dab1-/- (yotari) Mice. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/36406841a92b85a391ae18e96fe23168e25d6c34 [9] Paštar, V., Lozić, M., Kelam, N., Filipović, N., Bernard, B., Katsuyama, Y., Vukojević, K. (2021). Connexin Expression Is Altered in Liver Development of Yotari (dab1 -/-) Mice. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/9cd7314c89a6853eca4d852d67d92b79f5c6b532 [10] Mostafa, B. A., Helal, M. A., Nagy, A., El-Ghlban, S. (N/A). The Role of DAB1 and LRRC1 Gene Polymorphisms in the Pathogenesis of Vitiligo. *The Egyptian Journal of Medical Microbiology*. https://www.semanticscholar.org/paper/a5929d6d3a27e5e97b9ea3435c7c3ab05e8403e6 [